Cardinal under formal SEC investigation
Executive Summary
Securities & Exchange Commission initiates formal investigation into Cardinal's historical financial information relating in part to the accounting treatment of $22 mil. in revenues received from a vitamin price-fixing litigation settlement. SEC has been investigating the issue informally since October (1"The Pink Sheet" Oct. 13, 2003, In Brief). In April, Cardinal's audit committee retained independent counsel to conduct an internal review...
You may also be interested in...
Cardinal’s SEC request
Wholesaler receives an SEC request for "historical financial and related information," including information on the accounting treatment of a $22 mil. settlement in vitamin price-fixing litigation. Cardinal describes the request as part of an "informal inquiry" and says it is "highly confident in its accounting and financial disclosure practices, and intends to cooperate fully." Questions about the timing of Cardinal's recognition of the settlement funds were raised in April by the Wall Street Journal (1"The Pink Sheet" April 14, 2003, p. 28)...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: